Cong Tan, Xiaobin Zheng, Li Peng, Weiming Chen, Chuang Wang, Jiangli Han, Ling Gao
NEDD4 attenuates ICH injury by ubiquitinating LPAR1 and inhibiting RhoA/MMP9 signaling, thereby restoring AQP4 polarization and glymphatic function. Targeting the NEDD4/LPAR1 axis may offer a novel therapeutic strategy for ICH.
BACKGROUND: Intracerebral hemorrhage (ICH) induces severe neurological injury, and the glymphatic system plays a critical role in post-ICH brain recovery. This study investigated the role of neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4), an E3 ubiquitin ligase, in modulating glymphatic function and neuroprotection after ICH.
METHODS: An ICH model was established in mice via intrastriatal collagenase injection. Neurological function was assessed using modified Neurological Severity Score (mNSS). Histopathological damage was evaluated by hematoxylin and eosin (H&E) staining and Nissl staining. Evaluate Aquaporin-4 (AQP4) polarization and glymphatic system function through the co-localization of AQP4 and CD31, as well as cerebrospinal fluid (CSF) tracing with RITC-Dextran. Molecular mechanisms were explored in vitro using hemin-treated astrocytes. The physical interaction between NEDD4 and lysophosphatidic acid receptor 1 (LPAR1) was validated via co-immunoprecipitation. Ubiquitination assays and pathway analysis verified the ubiquitination of LPAR1 by NEDD4 and the subsequent suppression of the LPAR1/RhoA/MMP9 axis.
RESULTS: NEDD4 was significantly downregulated in peri-lesional astrocytes after ICH. NEDD4 overexpression improved neurological function, reduced hematoma volume and cerebral edema. Meanwhile, NEDD4 overexpression alleviated ICH-induced glymphatic dysfunction by promoting AQP4 polarization. Mechanistically, NEDD4 bound to LPAR1 and promoted its ubiquitin-mediated degradation, suppressing the RhoA/matrix MMP9 axis. Co-overexpression of LPAR1 abolished NEDD4-induced AQP4 polarization and glymphatic protection.
CONCLUSION: NEDD4 attenuates ICH injury by ubiquitinating LPAR1 and inhibiting RhoA/MMP9 signaling, thereby restoring AQP4 polarization and glymphatic function. Targeting the NEDD4/LPAR1 axis may offer a novel therapeutic strategy for ICH.